Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Mini-Review Article

A Mini Review: Origin, Treatments, Preventions, Real Facts and Viability of the Recent Pandemic of Novel Coronavirus-2019

Author(s): Prashant Kantrao Vibhute, Satish Babulal Jadhav, Satish Ashruba Dake and Bhaskar Sadashiv Dawane*

Volume 2, Issue 5, 2021

Published on: 26 August, 2020

Article ID: e300421185336 Pages: 6

DOI: 10.2174/2666796701999200826114852

Abstract

Background: Outbreak of Coronavirus Disease-2019 (COVID-19) has sent billions of people into lockdown. It has a negative impact on daily life, physical and mental health. Never before was seen such a type of pandemic sparked by a coronavirus. It increased anxiety in the community. Impacts of this disruption affect every sector such as health, finance, education, transport, agriculture, and economical growth of countries. Most of the countries experience insecurity in these sectors.

Objective: To reduce the spread of the novel Coronavirus-2019 and to bridge the knowledge gap of the research community, frontline health workers as well as those persons who are working in this regard to improve critical health challenges so that the community can plan effective prevention. In the present mini-review, we summarized the origin, route of transmission, current therapies of treatment, preventions, viability and real facts of fatal disease novel Coronavirus-2019 (2019-nCoV).

Result: Achieving division of a large population into small-small groups and take RT-PCR tests on a very large scale. It will help to identify and isolate an accurate infected person. Isolation of infected cases and quarantine reduce the transmissibility of COVID-19.

Conclusion: Knowledge about real-time evolution and transmission of the emerging pathogens helps to prevent its infection at all stages. To improve understanding of the risk, mechanism, and treatment in response to COVID-19 is required encouraging case studies, effective treatment therapies, drug discovery and developments. Make awareness in society about sanitation and avoid close contact to escape COVID-19 infection are the best ways of protection.

Keywords: Bat, COVID-19, coronavirus, pandemic, preventions, SARS-CoV-2, transmission.

Graphical Abstract
[1]
Wuhan Municipal Health Commission. Health Commission's briefing on the current pneumonia epidemic situation in our city Available from: http://wjw.wuhan.gov.cn/front/web/showDetail/2019123108989
[2]
Wu A, Peng Y, Huang B, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe 2020; 27(3): 325-8.
[http://dx.doi.org/10.1016/j.chom.2020.02.001] [PMID: 32035028]
[3]
World Health Organization Europe. 2019-nCoV outbreak is an emergency of international concern. Available from: http://www.euro.who.int/en/health-topics/health-mergencies/international-health-regulations/news/news/2020/2/2019-ncov-outbreak-is-an-emergency-of-international-concern
[4]
Worldometer. Covid-19 coronavirus pandemic. Available from: https://www.worldometers.info/coronavirus/
[5]
WHO. WHO statement on cases of COVID-19 surpassing 100 000 Available from: https://www.who.int/news-room/detail/07-03-2020-who-statement-on-cases-of-covid-19-surpassing-100-000
[6]
World Health Organization. Coronavirus disease (COVID-2019) situation repor. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/
[7]
Lancet. Challenges of coronavirus disease 2019. Lancet Infect Dis 2020; 20(3): 261.
[http://dx.doi.org/10.1016/S1473-3099(20)30072-4] [PMID: 32078810]
[8]
Tang B, Bragazzi NL, Li Q, Tang S, Xiao Y, Wu J. An updated estimation of the risk of transmission of the novel Coronavirus (2019-nCov). Infect Dis Model 2020; 5: 248-55.
[http://dx.doi.org/10.1016/j.idm.2020.02.001] [PMID: 32099934]
[9]
Worldometer. Coronavirus death toll. Available from: https://www.worldometers.info/coronavirus/coronavirus-death-toll/
[10]
Keusch GT, Pappaioanou M, Gonzalez MC. Sustaining global surveillance and response to emerging zoonotic diseases Washington (DC). National Academies Press (US) 2009.
[11]
Banerjee A, Kulcsar K, Misra V, Frieman M, Mossman K. Bats and coronaviruses. Viruses 2019; 11(1): 41.
[http://dx.doi.org/10.3390/v11010041] [PMID: 30634396]
[12]
Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382(8): 727-33.
[http://dx.doi.org/10.1056/NEJMoa2001017] [PMID: 31978945]
[13]
Arshad Ali S, Baloch M, Ahmed N, Arshad Ali A, Iqbal A. The outbreak of Coronavirus Disease 2019 (COVID-19)-An emerging global health threat. J Infect Public Health 2020; 13(4): 644-6.
[http://dx.doi.org/10.1016/j.jiph.2020.02.033] [PMID: 32199792]
[14]
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[15]
[16]
Sohrabi C, Alsafi Z, O’Neill N, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg 2020; 76: 71-6.
[http://dx.doi.org/10.1016/j.ijsu.2020.02.034] [PMID: 32112977]
[18]
Zhou P, Yang XL, Wang XG, et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin, bio Rxiv 2020.
[http://dx.doi.org/10.1101/2020.01.22.914952]
[19]
Sanchis-Gomar F, Lavie CJ, Perez-Quilis C, Henry BM, Lippi G. Angiotensin-converting enzyme 2 and antihypertensives (angiotensin receptor blockers and angiotensin converting enzyme inhibitors) in coronavirus disease 2019 (COVID-19). Mayo Clin Proc 2020; 95(6): 1222-30.
[http://dx.doi.org/10.1016/j.mayocp.2020.03.026] [PMID: 32376099]
[20]
Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med 2020; 26(4): 450-2.
[http://dx.doi.org/10.1038/s41591-020-0820-9] [PMID: 32284615]
[21]
Zhang T, Wu Q, Zhang Z. Probable pangolin origin of SARS-CoV-2 associated with the COVID 19 outbreak. Curr Biol 2020; 30(7): 1346-51.
[http://dx.doi.org/10.1016/j.cub. 2020.03.022]
[22]
Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579(7798): 270-3.
[http://dx.doi.org/10.1038/s41586-020-2012-7] [PMID: 32015507]
[23]
Xiao K, Zhai J, Feng Y, et al. Isolation and characterization of 2019-nCoV-like coronavirus from Malayan Pangolins Preprint on bioRxiv 2020.
[http://dx.doi.org/10.1101/2020.02.17.951335]
[24]
Zhang T, Wu Q, Zhang Z. Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak. Curr Biol 2020; 30(7): 1346-1351.e2.
[http://dx.doi.org/10.1016/j.cub.2020.03.022] [PMID: 32197085]
[25]
Li W, Shi Z, Yu M, et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 2005; 310(5748): 676-9.
[http://dx.doi.org/10.1126/science.1118391] [PMID: 16195424]
[26]
Hu B, Zeng LP, Yang XL, et al. Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus. PLoS Pathog 2017; 13(11)e1006698
[http://dx.doi.org/10.1371/journal.ppat.1006698] [PMID: 29190287]
[27]
Fan Y, Zhao K, Shi ZL, Zhou P. Bat coronaviruses in China. Viruses 2019; 11(3): 210-5.
[http://dx.doi.org/10.3390/v11030210] [PMID: 30832341]
[28]
Peng X, Xu X, Li Y, Cheng L, Zhou X, Ren B. Transmission routes of 2019-nCoV and controls in dental practice. Int J Oral Sci 2020; 12(1): 9-16.
[http://dx.doi.org/10.1038/s41368-020-0075-9] [PMID: 32127517]
[29]
Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020; 395(10223): 514-23.
[http://dx.doi.org/10.1016/S0140-6736(20)30154-9] [PMID: 31986261]
[30]
Phan LT, Nguyen TV, Luong QC, et al. Importation and human-to-human transmission of a novel coronavirus in Vietnam. N Engl J Med 2020; 382(9): 872-4.
[http://dx.doi.org/10.1056/NEJMc2001272] [PMID: 31991079]
[31]
Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020; 382(13): 1199-207.
[http://dx.doi.org/10.1056/NEJMoa2001316] [PMID: 31995857]
[32]
Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020; 382(10): 929-36.
[http://dx.doi.org/10.1056/NEJMoa2001191] [PMID: 32004427]
[33]
Shen K, Yang Y, Wang T, et al. Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts’ consensus statement. World J Pediatr 2020; 16(3): 223-31.
[http://dx.doi.org/10.1007/s12519-020-00343-7] [PMID: 32034659]
[34]
Lu H. Drug treatment options for the 2019-new Coronavirus (2019-nCoV). Biosci Trends 2020; 14(1): 69-71.
[http://dx.doi.org/10.5582/bst.2020.01020] [PMID: 31996494]
[35]
Maxmen A. More than 80 clinical trials launch to test coronavirus treatments. Nature 2020; 578(7795): 347-8.
[http://dx.doi.org/10.1038/d41586-020-00444-3] [PMID: 32071447]
[36]
Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov 2020; 6: 14-8.
[http://dx.doi.org/10.1038/s41421-020-0153-3] [PMID: 32194980]
[37]
Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab Syndr 2020; 14(3): 241-6.
[http://dx.doi.org/10.1016/j.dsx.2020.03.011] [PMID: 32247211]
[38]
McChesney EW. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am J Med 1983; 75(1A): 11-8.
[http://dx.doi.org/10.1016/0002-9343(83)91265-2] [PMID: 6408923]
[39]
Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020; 6: 16.
[http://dx.doi.org/10.1038/s41421-020-0156-0] [PMID: 32194981]
[40]
Sahraei Z, Shabani M, Shokouhi S, Saffaei A. Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. Int J Antimicrob Agents 2020; 55(4)105945
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105945] [PMID: 32194152]
[41]
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269-71.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]
[42]
Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against Coronavirus: what to expect for COVID-19? Int J Antimicrob Agents 2020; 55(5)105938
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105938] [PMID: 32171740]
[43]
Duan Y, Zhu HL, Zhou C. Advance of promising targets and agents against COVID-19 in China. Drug Discov Today 2020; 25(5): 810-2.
[http://dx.doi.org/10.1016/j.drudis.2020.02.011] [PMID: 32198066]
[44]
Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020; 14(1): 72-3.
[http://dx.doi.org/10.5582/bst.2020.01047] [PMID: 32074550]
[45]
Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 2020; 14(1): 58-60.
[http://dx.doi.org/10.5582/ddt.2020.01012] [PMID: 32147628]
[46]
Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020.105949105949
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105949] [PMID: 32205204]
[47]
Liu F, Xu A, Zhang Y, et al. Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression. Int J Infect Dis 2020; 95: 183-91.
[http://dx.doi.org/10.1016/j.ijid.2020.03.013] [PMID: 32173576]
[48]
Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020.109102433
[http://dx.doi.org/10.1016/j.jaut.2020.102433] [PMID: 32113704]
[49]
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507-13.
[http://dx.doi.org/10.1016/S0140-6736(20)30211-7] [PMID: 32007143]
[51]
Nature plants. Redeploying plant defences. Nat Plants 2020; 6(3): 177.
[http://dx.doi.org/10.1038/s41477-020-0628-0] [PMID: 32170291]
[52]
WHO. WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19. Available from: https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19
[53]
Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. N Engl J Med 2020; 382(19): 1787-99.
[http://dx.doi.org/10.1056/NEJMoa2001282] [PMID: 32187464]
[54]
Oren O, Yang EH, Gluckman TJ, Michos ED, Blumenthal RS, Gersh BJ. Use of chloroquine and hydroxychloroquine in covid-19 and cardiovascular implications: understanding safety discrepancies to improve interpretation and design of clinical trials. Circ Arrhythm Electrophysiol 2020; 13(6)e008688
[http://dx.doi.org/10.1161/CIRCEP.120.008688] [PMID: 32436730]
[55]
Jeevaratnam K. Chloroquine and hydroxychloroquine for COVID-19: implications for cardiac safety. Eur Heart J Cardiovasc Pharmacother 2020.
[http://dx.doi.org/10.1093/ehjcvp/pvaa041]
[56]
Song P, Karako T. COVID-19: Real-time dissemination of scientific information to fight a public health emergency of international concern. Biosci Trends 2020; 14(1): 1-2.
[http://dx.doi.org/10.5582/bst.2020.01056] [PMID: 32092748]
[57]
Yang Y, Peng F, Wang R, et al. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun 2020.109102434
[http://dx.doi.org/10.1016/j.jaut.2020.102434] [PMID: 32143990]
[58]
Pathan A. Current off-label pharmacotherapeutics in the management of novel coronavirus disease (COVID-19). Neuropharmac J 2020; 5: 108-12.
[http://dx.doi.org/10.37881/1.511]
[59]
WHO. Coronavirus disease (COVID-19) advice for the public. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public
[60]
Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19) StatPearls. Treasure Island, FL: StatPearls Publishing 2020.
[61]
WHO. Coronavirus disease (COVID-19) advice for the public: Mythbusters. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/mythbusters
[62]
Xu Y, Li X, Zhu B, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat Med 2020; 26(4): 502-5.
[http://dx.doi.org/10.1038/s41591-020-0817-4] [PMID: 32284613]
[63]
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061-9.
[http://dx.doi.org/10.1001/jama.2020.1585] [PMID: 32031570]
[64]
Hosoda T, Sakamoto M, Shimizu H, Okabe N. SARS-CoV-2 enterocolitis with persisting to excrete the virus for approximately two weeks after recovering from diarrhea: A case report. Infect Control Hosp Epidemiol 2020; 41(6): 753-4.
[http://dx.doi.org/10.1017/ice.2020.87] [PMID: 32188528]
[65]
Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020; 8(4)e21
[http://dx.doi.org/10.1016/S2213-2600(20)30116-8] [PMID: 32171062]
[66]
van Doremalen N, Bushmaker T, Holbrook MG, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020; 382: 1564-7.
[http://dx.doi.org/10.1056/NEJMc2004973]
[67]
Khan S, Peng L, Siddique R, et al. Impact of COVID-19 infection on pregnancy outcomes and the risk of maternal-to-neonatal intrapartum transmission of COVID-19 during natural birth. Infect Control Hosp Epidemiol 2020; 41(6): 748-50.
[http://dx.doi.org/10.1017/ice.2020.84] [PMID: 32279693]
[68]
Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet 2020; 395(10226): 809-15.
[http://dx.doi.org/10.1016/S0140-6736(20)30360-3] [PMID: 32151335]
[69]
Luo Y, Yin K. Management of pregnant women infected with COVID-19. Lancet Infect Dis 2020; 20(5): 513-4.
[http://dx.doi.org/10.1016/S1473-3099(20)30191-2] [PMID: 32220285]
[70]
Yu N, Li W, Kang Q, et al. Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study. Lancet Infect Dis 2020; 20(5): 559-64.
[http://dx.doi.org/10.1016/S1473-3099(20)30176-6] [PMID: 32220284]
[71]
Schwartz DA. An Analysis of 38 pregnant women with COVID-19, their newborn infants, and maternal-fetal transmission of SARS-CoV-2: maternal coronavirus infections and pregnancy outcomes. Arch Pathol Lab Med 2020; 20(5): 559-64.
[http://dx.doi.org/10.5858/arpa.2020-0901-SA] [PMID: 32180426]
[72]
Liu D, Li L, Wu X, et al. Pregnancy and perinatal outcomes of women with coronavirus disease (COVID-19) pneumonia: a preliminary analysis. AJR Am J Roentgenol 2020; 215(1): 127-32.
[http://dx.doi.org/10.2214/AJR.20.23072] [PMID: 32186894]
[73]
Chen Y, Peng H, Wang L, et al. Infants born to mothers with a new coronavirus (COVID-19). Front Pediatr 2020; 8(8): 104.
[http://dx.doi.org/10.3389/fped.2020.00104] [PMID: 32266184]
[74]
CDC. Breastfeeding and caring for newborns Available from: https://www.cdc.gov/coronavirus/2019-ncov/prepare/pregnancy-breastfeeding.html
[75]
Tegethoff M, Pryce C, Meinlschmidt G. Effects of intrauterine exposure to synthetic glucocorticoids on fetal, newborn, and infant hypothalamic-pituitary-adrenal axis function in humans: a systematic review. Endocr Rev 2009; 30(7): 753-89.
[http://dx.doi.org/10.1210/er.2008-0014] [PMID: 19837868]

© 2022 Bentham Science Publishers | Privacy Policy